Literature DB >> 8388698

Types of cyclic AMP binding proteins in human breast cancers.

W R Miller1, M J Hulme, Y S Cho-Chung, R A Elton.   

Abstract

Total level and type of cyclic AMP binding proteins have been measured in 117 breast cancers. Six major molecular species of binding proteins were detected. The pattern and relative proportion of binding proteins varied between individual tumours. However, there were highly significant correlations between the expression of different binding proteins, including positive relationships between 52 and 67 kD proteins, 43 kD and both 39 and 37 kD proteins and inverse correlations between 48 and 52 kD, 37 and 67 kD proteins. The expression of three binding proteins (48, 43 and 39 kD) was also positively related to total binding whereas that of the remaining three bindings proteins (67, 52 and 37 kD) was negatively correlated with total levels. It may be that differential expression of certain types of binding protein are the underlying rationale for our previously published finding that tumours with high levels of high binding protein are associated with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388698     DOI: 10.1016/s0959-8049(05)80207-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression.

Authors:  Y S Cho; Y G Park; Y N Lee; M K Kim; S Bates; L Tan; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Ala99ser mutation in RI alpha regulatory subunit of protein kinase A causes reduced kinase activation by cAMP and arrest of hormone-dependent breast cancer cell growth.

Authors:  G R Lee; S N Kim; K Noguchi; S D Park; S H Hong; Y S Cho-Chung
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

3.  Antisense DNAs as multisite genomic modulators identified by DNA microarray.

Authors:  Y S Cho; M K Kim; C Cheadle; C Neary; K G Becker; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

4.  PKA knockdown enhances cell killing in response to radiation and androgen deprivation.

Authors:  Harvey H Hensley; Jean-Michel Hannoun-Levi; Paul Hachem; Zhaomei Mu; Radka Stoyanova; Li-Yan Khor; Sudhir Agrawal; Alan Pollack
Journal:  Int J Cancer       Date:  2010-10-19       Impact factor: 7.396

5.  Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.

Authors:  Li-Yan Khor; Kyounghwa Bae; Tahseen Al-Saleem; Elizabeth H Hammond; David J Grignon; William T Sause; Miljenko V Pilepich; Paul P Okunieff; Howard M Sandler; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

6.  The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.

Authors:  Alan Pollack; Kyounghwa Bae; Li-Yan Khor; Tahseen Al-Saleem; M Elizabeth Hammond; Varagur Venkatesan; Roger W Byhardt; Sucha O Asbell; William U Shipley; Howard M Sandler
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 7.  Tissue biomarkers for prostate cancer radiation therapy.

Authors:  P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese
Journal:  Curr Mol Med       Date:  2012-07-01       Impact factor: 2.222

8.  8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor.

Authors:  A Budillon; E Di Gennaro; M Caraglia; D Barbarulo; A Abbruzzese; P Tagliaferri
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

9.  Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers.

Authors:  A D Ramage; D J Burns; W R Miller
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.